BioMarin Pharmaceutical (BMRN) Agrees $490 Million Deal For Oral Rare Bone Disease Program

Ultragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.

BioMarin Pharmaceutical (BMRN) rose 6.9% after Q2 results. Myriad Genetics (MYGN) fell 41.8% with revenue down 10.5% YoY, missing estimates. Halozyme Therapeutics (HALO) gained 25% with revenue up 47.7% YoY, beating expectations. Vertex Pharmaceuticals (VRTX) increased 16.3% with revenue up 12.5% YoY, topping forecasts.

BioMarin (BMRN) agreed to acquire Alesta Therapeutics for $275M upfront, with up to $215M in milestones. The deal expands BioMarin's rare disease pipeline, adding ALE1, a potential oral treatment for hypophosphatasia. BioMarin shares rose 4.7% premarket. The acquisition will be funded with existing cash and is expected to close this quarter.

BioMarin Pharmaceutical (BMRN) acquired Alesta Therapeutics for $275M upfront, gaining rights to ALE1, an oral treatment for hypophosphatasia (HPP). ALE1 is in early trials, with BioMarin potentially paying $215M more if milestones are met. The deal aligns with BioMarin's focus on rare skeletal diseases and follows its $4.8B acquisition of Amicus Therapeutics.

BioMarin Pharmaceutical (BMRN) rose 3.5% after acquiring Alesta Therapeutics for $275M upfront, with up to $215M in milestones. Analysts reacted positively, with Barclays and Piper Sandler raising price targets. The stock closed at $69.33, near its 52-week high.

BioMarin Pharmaceutical agreed to acquire Alesta Therapeutics for $275 million upfront, with up to $215 million in milestone payments. The deal focuses on ALE1, an oral treatment for hypophosphatasia (HPP), currently in Phase 1/2a trials. BioMarin plans to fund the acquisition with cash and expects it to close in Q3 2026, subject to conditions.